Just a couple of months after completing the divestment of its Rx prescription generics business to Altaris Capital Partners for $1.55bn, Perrigo has splashed out with a €1.8bn ($2.1bn) deal to acquire consumer healthcare player HRA Pharma, completing the company’s transformation into a fully self-care focused company. (Also see "Perrigo Reaches $1.5bn Deal With Altaris For Rx Business" - Generics Bulletin, 2 March, 2021.)
Insisting that exiting the Rx and “non-strategic” businesses had allowed Perrigo to “reduce volatility and simplify [our] business model,” the...
